Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
ConditionBurns
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSkingenix, Inc.
About this trial
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Eligibility criteria
Qualifiers
Adults, 18 years of age or older on the day of signing the informed consent.
Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns.
Able and willing to give informed consent and comply with study procedures.
Disqualifiers
infected.
circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome.
partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention.
Severe inhalation injury or other significant non-burn trauma.
Trial design
Treatments tested in this trial
- Investigational Drug, MW-III
- Silvadene® Cream 1% [Silver Sulfadiazine]
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov